To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. They specialize in the discovery and development of molecular targeted therapies, and are listed in the NASDAQ Biotechnology Index.
Additional recommended knowledge
OSI's oncology products include Tarceva (Erlotinib), a small molecule inhibitor of the epidermal growth factor receptor (EGFR), which was first discovered and developed by OSI. Tarceva is the only EGFR inhibitor to have demonstrated the ability to improve overall survival in advanced non-small cell lung cancer and advanced pancreatic cancer. The company's research and development capability includes high-throughput screening, chemical libraries, medicinal and combinational chemistry and automated drug profiling technology platforms.
OSI has approximately 500 staff in research and development, regulatory, sales, marketing, commercial and business.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "OSI_Pharmaceuticals". A list of authors is available in Wikipedia.|